Avalyn Pharma, Inc. (AVLN)
37.39
+1.95
(+5.50%)
USD |
NASDAQ |
Sep 04, 16:00
37.00
-0.39
(-1.04%)
After-Hours: 20:00
Avalyn Pharma Enterprise Value : 1.322B for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 1.322B |
| September 03, 2026 | 1.236B |
| September 02, 2026 | 1.242B |
| September 01, 2026 | 1.229B |
| August 31, 2026 | 1.204B |
| August 28, 2026 | 1.203B |
| August 27, 2026 | 1.283B |
| August 26, 2026 | 1.307B |
| August 25, 2026 | 1.358B |
| August 24, 2026 | 1.336B |
| August 21, 2026 | 1.366B |
| August 20, 2026 | 1.311B |
| August 19, 2026 | 1.392B |
| August 18, 2026 | 1.387B |
| August 17, 2026 | 1.360B |
| August 14, 2026 | 1.405B |
| August 13, 2026 | 1.286B |
| August 12, 2026 | 1.322B |
| August 11, 2026 | 1.237B |
| August 10, 2026 | 1.197B |
| August 07, 2026 | 1.168B |
| August 06, 2026 | 1.114B |
| August 05, 2026 | 1.083B |
| August 04, 2026 | 1.027B |
| August 03, 2026 | 928.18M |
| Date | Value |
|---|---|
| July 31, 2026 | 941.03M |
| July 30, 2026 | 964.09M |
| July 29, 2026 | 910.44M |
| July 28, 2026 | 896.70M |
| July 27, 2026 | 889.16M |
| July 24, 2026 | 903.79M |
| July 23, 2026 | 982.71M |
| July 22, 2026 | 937.93M |
| July 21, 2026 | 951.67M |
| July 20, 2026 | 933.94M |
| July 17, 2026 | 919.31M |
| July 16, 2026 | 803.16M |
| July 15, 2026 | 879.41M |
| July 14, 2026 | 918.42M |
| July 13, 2026 | 898.92M |
| July 10, 2026 | 908.67M |
| July 09, 2026 | 946.80M |
| July 08, 2026 | 947.68M |
| July 07, 2026 | 924.63M |
| July 06, 2026 | 890.49M |
| July 02, 2026 | 982.71M |
| July 01, 2026 | 1.002B |
| June 30, 2026 | 1.124B |
| June 29, 2026 | 1.640B |
| June 26, 2026 | 1.627B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -43.06M |
| CorMedix, Inc. | 542.53M |
| Eloxx Pharmaceuticals, Inc. | -1.42M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 1.389M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.94M |
| Total Expenses (Quarterly) | 28.94M |
| EPS Diluted (Quarterly) | -0.6527 |
| Earnings Yield | -5.64% |
| Normalized Earnings Yield | -5.640 |